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CancerFOXO transcription factors have emerged as rheostats that coordinate the activities of Akt and targets of
rapamycin complexes (TORCs). This review summarizes the regulatory circuits mediated by the activation of
FOXO, which in turn modulate Akt and TORCs activities. The biological signiﬁcance of these regulatory circuits
is discussed in this article. This article is part of a Special Issue entitled: P13K-AKT-FoxO axis in cancer and
aging.-AKT-FoxO axis in cancer and
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The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway,
which leads to the inhibition of the forkhead box O (FOXO)
transcription factors is highly conserved across metazoans (Fig. 1). In
both Caenorhabditis elegans andDrosophila, FOXO transcription factors
are inhibited predominantly by the activation of insulin (Ins) or
insulin-like growth factor receptors (Ins/IGF1R). Insulin and insulin-
like growth factor receptors have similar functions across species. They
exert their effects through the phosphorylation and activation of
insulin receptor substrates (IRS), which provide docking sites for the
interaction and activation of downstream effectors. In mammals,
FOXO transcription factors are also inhibited by any extracellular
signal that activates the serine/threonine kinase, Akt, which is also
known as protein kinase B (PKB). Akt is activated by extracellular
signals that activate PI3K. PI3K phosphorylates phosphoinositols to
generate phosphatidylinositol 3′ phosphate (PIP3). The binding of
PIP3 to the pleckstrin homology (PH) domain of Akt is the rate-limiting
step inAkt activation. This binding elicits the translocation of Akt to the
membrane, where it is fully activated by other kinases. Akt isphosphorylated at threonine residue 308 (Thr 308) by PDK1 and at a
serine residue (Ser 473) by mTORC2, which is a rapamycin-resistant
complex containing the mammalian target of rapamycin (mTOR) (for
review, see [1]) (Fig. 2). Antagonizing PI3K activity negatively
regulates Akt activity. For instance, Akt activity is negatively regulated
by phospholipid phosphatases that dephosphorylate PIP3. The major
phospholipid phosphatase that regulates Akt activity is the tumor
suppressor PTEN, which dephosphorylates the 3′ phosphate of PIP3
and thereby negates the activity of PI3K. The most evolutionarily
conserved downstream effectors of Akt are the FOXO transcription
factors, which include FOXO1, 3, 4, and 6 in mammals [2]. Another
conserved target of Akt is the target of rapamycin complex 1 (TORC1)
(reviewed in [1], which is indirectly activated by Akt (Fig. 1)).
FOXO transcription factors, across species, have highly conserved
phosphorylation sites that are phosphorylated by Akt. The phosphor-
ylation of FOXOs by Akt in the nucleus creates a 14-3-3 binding site.
The binding of 14-3-3 to FOXO masks the nuclear localization signal
(NLS) and prevents nuclear translocation, thereby inhibiting the
activities of FOXO (reviewed in [3]). FOXO transcription factors, across
species, possess other phosphorylation sites that can be phosphory-
lated by the stress inducible kinases, Jun N-terminus kinase (JNK) and
STE20-like protein kinase 1 (MST1). The activation of FOXO, initiated
by the phosphorylation by JNK and MST1, is dominant to the
inhibitory phosphorylation by Akt (reviewed in [3], Fig. 2).
The PI3K/Akt/FOXOpathwaywas delineated in C. elegans in a genetic
screen for lifespan extension [4–7]. Mutations that attenuate the
activities of the insulin receptor ortholog, DAF-2, and the PI3K ortholog,
AGE-1, inhibit Akt activity andcan also extend the lifespanofworms. The
A. Mammals B. Flies C. Worms
Fig. 1. The interplay between FOXO, TOR, and Akt. A. The signaling pathway from Insulin/IGF1 receptor through IRS, PI3K, and Akt in mammalian cells. Akt inhibits FOXO through
direct phosphorylation, and indirectly activates mTORC1, which in turn elevates protein synthesis. mTORC1 and its downstream effector, S6K, elicit negative feedback loops to inhibit
Akt. When activated FOXO induces the expression of Sestrin 3, which activates AMPK to inhibit mTORC1. FOXO also induces Insulin/IGF1 receptors, IRS2, and Rictor expression to
activate Akt (see text for details). B. The signaling pathway from Insulin/IGF1 receptor through IRS, PI3K, and Akt in ﬂies. The mechanisms of FOXO inhibition andmTORC1 activation
by Akt are conserved in ﬂies andmammals. In ﬂies, themechanism of TORC1 inhibition by FOXO through Sestrin and AMPK is conserved. In addition, FOXO elevates the expression of
4E-BP downstream of TORC1, and induces the expression of Insulin/IGF1 receptor to activate Akt (see text for details). C. The signaling pathway from the Insulin/IGF1 receptor
through PI3K, and Akt in worms. The inhibition of FOXO by Akt is conserved in worms. However, the mechanism of TORC1 activation by Akt is not conserved. Akt can activate TORC1
through inhibition of FOXO because FOXO inhibits the expression of Raptor, which is required for TORC1 activity (see text for details).
1966 N. Hay / Biochimica et Biophysica Acta 1813 (2011) 1965–1970increase in lifespan by the inhibition of PI3K andAkt activities is largely a
consequence of DAF-16 activation, which is the C-elegans ortholog of
FOXO. Mutations that inhibit the activity DAF-16 revert the lifespan
extension phenotype [8,9]. The role of the PI3K/Akt/FOXO signaling in
longevity appears to be conserved across species (reviewed in [3,10]).Fig. 2. The regulation of FOXO activity by Akt activation, and by JNK and MST1 activation. Ak
activates PDK1 and mTORC2, which are composed of mTOR, Rictor, Sin1 and mLST8. PDK1
FOXO and creates docking site for 14-3-3. The binding of 14-3-3 to FOXO excludes FOXO fro
phosphorylate FOXO at two different sites. The phosphorylation by JNK or MST1 promotes2. Regulatory circuits that mediate interplays between FOXO,
TOR and Akt
Like FOXO transcription factors, TOR complexes, which share TOR as
their catalytic subunit, are highly conserved across evolution. TORt is activated by PI3K downstream of tyrosine kinase growth factor receptors. PI3K also
and mTORC2 phosphorylate Akt for full activation. Upon activation Akt phosphorylates
m the nucleus. Oxidative and genotoxic stresses activate JNK and MST1. JNK and MST1
the nuclear localization of FOXO despite phosphorylation by Akt (see text for details).
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complex2 (TORC2) is a conservedactivatorof Akt. Thedeﬁning subunits
of the two mammalian TORCs (mTORCs) are the regulatory associated
proteins of mTOR (Raptor) in mTORC1 and Rapamycin-insensitive
companion of mTOR (Rictor) in mTORC2, which are also evolutionarily
conserved. mTORC1 is composed of mTOR, Raptor, mLST8 as the core
kinase complex, and the accessory factors PRAS40 and Deptor [11]. One
mechanism by which Akt activates mTORC1 is through direct
phosphorylation of tuberous sclerosis complex 2 (TSC2), which
otherwise inhibits mTORC1 activity (Fig. 1; reviewed in [12]). Tuberous
sclerosis complex 1 (TSC1) and TSC2 form a heterodimer that possesses
GAPactivity and inhibits theactivityof Rheb, a small GTPase required for
mTOR activation (Fig. 1; reviewed in [1]). TSC2 can be activated when
intracellular levels of ATP are reduced and AMPK activity is elevated.
AMPK directly phosphorylates TSC2, leading to the induction of
mTORC1 inhibition [13]. Additionally, AMPK inhibits mTORC1 through
direct phosphorylation of Raptor [14], which is a conservedmechanism
that might be the major pathway by which AMPK affects TORC1 in ﬂies
(Fig. 1). However, AMPKphosphorylation sites arenot fully conserved in
the Drosophila TSC2. Akt also activates mTORC1 by maintaining
intracellular ATP levels and reducing AMPK activity [15].
In TSC2- or TSC1-null cells, mTORC1 is constitutively activated,
independent of growth factors and Akt, which is consistent with an
inhibitory role for TSC2. In contrast, Akt activity is markedly reduced
in these cells. This reduction has been attributed to a negative
feedback mechanism involving an inhibitory effect of S6 Kinase
(a downstream effector of mTORC1) on insulin receptor substrate-1
(IRS1) or IRS2, which mediates PI3K activation by insulin and IGF-1
[23]. Additional negative regulatory loops elicited by mTORC1 that
inhibit Akt activity may also exist [1].
The other mTOR complex, mTORC2, is composed of Rictor, mLST8
and mSin1 as the core kinase complex (Fig. 2), and the accessory
factors Deptor and Protor-1 [11]. mTORC2 is the carboxy-terminus
hydrophobic motif (HM) kinase for Akt and other AGC kinases.
One major conserved function of mTORC1 is to increase mRNA
translation (Fig. 1) via the phosphorylation and activation of S6 kinase
and by the phosphorylation and inhibition of the eukaryotic
translation initiation factor 4E (eIF4E) binding protein (4E-BP),
which is a repressor of mRNA translation [12]. The hypopho-
sphorylated active form of 4E-BP binds eIF4E and blocks the
interaction of eIF4E with eIF4G, thereby inhibiting cap-dependent
mRNA translation. In addition to protein synthesis, mTORC1 has
another conserved anabolic activity that involves fatty acid biosyn-
thesis through the activation of the sterol-regulatory-element-
binding protein (SREBP1) [16]. SREBP1 is a transcription factor that
facilitates fatty acid synthesis by regulating the expression of enzymes
associated with fatty acids synthesis. Finally, mTORC1 has a conserved
function in inhibiting autophagy by phosphorylating proteins that are
required for its initiation [17].
Unlike in mammals and ﬂies, the insulin/IGF1-Akt axis has not
been shown to regulate C. elegans TORC1 (CeTORC1). The C. elegans
genome lacks readily identiﬁable homologs of TSC1 and TSC2 [18],
whichmediate the effect of Akt onmTORC1, but C. elegans Akt (CeAkt)
can indirectly increase CeTORC1 activity via the phosphorylation and
inhibition of the C. elegans FOXO transcription factor, DAF-16. DAF-16
has a potent negative effect on DAF-15 (C. elegans Raptor) expression
[19], and therefore, the inhibition of DAF-16 by CeAkt could maintain
the availability of Raptor/DAF-15 to form CeTORC1. Thus, in nematodes,
Akt indirectly activates TORC1 through the inhibition of DAF-16 and the
elevation of Raptor expression (Fig. 1). In contrast, the activation of
DAF-16 by the stress inducible kinase, JNK, would inhibit TORC1. It is
not known if, like in mammals and ﬂies, the activation of CeTORC1
elicits a negative feedback loop to inhibit IGF1/insulin signaling and Akt.
If such a negative feedback loop exists in C. elegans, it would imply that
the activation of DAF-16 by oxidative stresswould lead to the inhibition
of TORC1 and the activation of Akt.In Drosophila, there are two major identiﬁed regulatory circuits by
which FOXO regulates TORC1 and Akt activity (Fig. 1). It was shown
that in Drosophila, 4E-BP is a transcriptional target of FOXO. Therefore,
following the activation of FOXO in ﬂies, 4E-BP is elevated and
counteracts TORC1 activity on the initiation of cap-dependent mRNA
translation. However, at the same time, FOXO upregulates the tran-
scription of the insulin receptor (InsR) mRNA, which possesses an
internal ribosome initiation site (IRES). Therefore, the high level of
insulin receptor mRNA induced by FOXO is coupled to a high level of
InsR protein through IRES-dependent mRNA translation, even though
cap-dependent mRNA translation is inhibited. Consequently, the
inhibition of cap-dependent mRNA translation by FOXO could be
alleviated through the high levels of insulin receptor and the
hyperactivation of Akt and TORC1 [20,21].
The upregulation of InsR by FOXO appears to be conserved in
mammals, as it was found that FOXO activates InsR transcription, at
least in liver and muscle cells [20]. It was also shown that FOXO
elevates IRS2 mRNA levels, thereby potentially elevating signaling
downstream of InsR or IGF1R. Notably, IRS2 protein is degraded by a
mechanism that is dependent on mTORC1 or its downstream effector,
S6K1 [22]. More recently, it was shown that FOXO elevates HER2/
HER3 tyrosine kinase receptor expression in several cancer cell lines
[23] in addition to InsR and IGF1R. The elevation of tyrosine kinase
receptors by FOXO establishes feedback mechanisms that amplify
growth factor signaling and limit prolonged FOXO activation.
Another regulatory circuit through which FOXO affects TORC1 in
Drosophila was recently uncovered [24]. It was found that FOXO
indirectly activates AMPK, which in turn activates TSC2 and inhibits
TORC1 activity. FOXO activates AMPK through the transcriptional
upregulation of Sestrin. Sestrins are a family of highly conserved
proteins that were originally discovered in mammals as antioxidants
[25,26]. However, it was found that they have an additional function
that leads to the activation of AMPK, although the exact mechanism
by which Sestrin activates AMPK is not fully understood [27]. This
pathway, by which FOXO inhibits TORC1 in ﬂies, manifests in
conditions of oxidative stress, whereby FOXO is activated by stress
inducible kinases, JNK or MST1.
The FOXO-Sestrin-AMPK-TORC1 axis is conserved in mammalian
cells (Fig. 1). Mammalian FOXO1 was shown to bind to the promoter
region of Sestrin 3, and transcriptionally elevate Sestrin 3 expression
[28]. Sestrin 3 is one of three members of the Sestrin family. Sestrin 1
and 2 were shown to be transcriptional targets of p53 [27], whereas
Sestrin 3 is induced by FOXO [28,29]. Sestrin 3 has a dual activity
downstream of FOXO. In its role as a scavenger of ROS, Sestrin 3
mediates ROS detoxiﬁcation by FOXO and inhibits cellular senescence
[29], and as an activator of AMPK, it inhibits mTORC1 in a TSC2-
depedent manner [28]. Thus, by analogy to p53, which induces the
expression of Sestrin 1 and 2, reduces ROS levels and inhibits
mTORC1, FOXO induces the expression of Sestrin 3 to reduce ROS
and inhibit mTORC1 (Fig. 3). Notably, FOXO itself is subjected to
regulation by the energy status of cells, as AMPK was shown to
phosphorylate FOXO and facilitate its nuclear localization [30].
Therefore, the FOXO-Sestrin-AMPK axis could be further augmented
by AMPK through a feed-forward mechanism.
The inhibition of mTORC1 by FOXO could lead to the activation of
Akt via the inhibition of the negative feedback loop driven bymTORC1
and S6K1 (Fig. 1). However, FOXO also elevates transcriptional
expression of Rictor through a DNA-binding independent mechanism.
This elevation of Rictor by FOXO increases mTORC2 and Akt activity.
The increase in Akt activity is due to the increase in assembly and
activity of mTORC2, which occurs at the expense of the assembly and
activity of mTORC1 [28]. Therefore, the elevation of Rictor by FOXO
constitutes another mechanism bywhich FOXO could inhibit mTORC1
in a TSC-independent mechanism.
As indicated above, FOXO elevates both InsR and IRS2 mRNA but
IRS2 protein is degraded by mTORC1. Therefore, the inhibition of
Fig. 3. Analogy between p53 and FOXO activities. By analogy to p53, which induces
Sestrin1 and Sestrin2 transcriptionally, FOXO induces Sestrin3 transcriptionally. p53
reduces ROS and inhibits mTORC1 through the induction of Sestrin1 and 2 expression,
while FOXO reduces ROS and inhibits mTORC1 through the induction of Sestrin3
expression.
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and IRS2 (Fig. 1).
There are other potential mechanisms by which FOXO could
regulate Akt and mTOR activities. For instance, FOXO suppresses the
expression of the pseudokinase, tribbles 3 (Trb3) [31], and it was
reported that Trb3 inhibits Akt activity [49]. Thus, by suppressing Trb3
expression, FOXO could activate Akt. It was also reported that FOXO
elevates the expression of Bnip3 [50]. Because Bnip3 was shown to
inhibit mTORC1 activity downstream of TSC2 by interfering with Rheb
activity [51], FOXO could inhibit mTORC1 through the induction of
Bnip3 expression. Finally, it was recently reported that FOXO3 induces
the transcriptional expression of TSC1 and inhibit mTORC1 [32].3. The biological signiﬁcance of the FOXO, TOR, AKT interplay
The inhibitory effect of FOXO on TORC1 could explain, at least in
part, some of FOXO activities that phenocopy TORC1 inhibition. For
instance, the activation of FOXO extends lifespan, whereas the
activation of TORC1 reduces it [33]. Thus, it is possible that one
mechanism by which FOXO extends lifespan is through the inhibition
of TORC1. Heterozygous DAF-15 (Raptor ortholog) worms and CeTOR
RNAi-treated worms have an extended adult life span [19,34], similar
to DAF-2, the ortholog of insulin/IGF1 receptor and age-1 (CePI-
3kinase), mutant worms and DAF-16 (FOXO ortholog) overexpressing
strains. In addition, DAF-15 and CeTOR homozygous mutant larvae
accumulate lipids, similar to DAF-2 mutant dauer larvae [19,34]. Thus,
at least some of the effects of the DAF-2/Akt/DAF-16 pathway (such as
longevity) may be mediated through regulation of CeTOR/DAF-15.
In Drosophila, it was shown that 4E-BP extends lifespan and is
required for the extension of lifespan by dietary restriction (DR) [33].
Although FOXO-null ﬂies respond normally to DR, it cannot be
completely excluded that the transcriptional induction of 4E-BP by
FOXO, in ﬂies, contributes to the ability of FOXO to extend lifespan.
Supporting this possibility are the ﬁndings, which show that
overexpression of 4E-BP in FOXO-null ﬂies, which are sensitive to
oxidative stress, restores oxidative stress resistance [35]. Further-
more, either the overexpression of 4E-BP or activation of FOXO delays
proteostasis during muscle aging in ﬂies, and FOXO exerts its effect on
muscle aging through the induction of 4E-BP expression [36].
The FOXO-Sestrin-AMPK-TORC1 axis in ﬂies was shown to
alleviate several age-related pathologies in response to oxidative
stress, such as muscle degeneration, cardiac arrhythmia, and lipid
accumulation [24]. Because FOXO can also improve cardiac aging in
ﬂies by increasing 4E-BP levels [37], it could affect ﬂy aging
pathologies by both decreasing TORC1 activity and increasing 4E-BP
levels.FOXO transcription factors, across species, promote resistance to
oxidative stress, premature aging, and cellular senescence. This
activity of FOXO was attributed largely to its ability to induce the
expression of antioxidants. By contrast, the anabolic activities of
TORC1 induce oxidative stress, and chronic activation of mTORC1
induces premature senescence [33,38–40]. Thus, the inhibition of
TORC1 by FOXO, which occurs across species by different mecha-
nisms, could add another way bywhich FOXO reduces oxidative stress
and inhibits premature aging and cellular senescence.
FOXO transcription factors are thought to have tumor suppressive
activity [41] whereas mTORC1 is frequently activated in cancer cells
[1]. Both the activation of FOXO and the inhibition of mTORC1 elicit
cell cycle arrest or attenuation of cell proliferation. Thus, the inhibition
of mTORC1 could account for some of FOXO's tumor suppressor
activities.
Other consequences of FOXO activation and mTORC1 inhibition
that phenocopy each other include cellular atrophy and autophagy.
Both the activation of FOXO and the inhibition of mTORC1 elicit
cellular atrophy [42–45]. Therefore, it is possible that the inhibition of
mTORC1, by activated FOXO, contributes to cellular atrophy. The
activation of mTORC1 is known to inhibit autophagy, and it was also
shown that autophagy could be mediated by the activation of FOXO
[46].
As described above, the inhibitory effect of FOXO on TORC1, at
least in ﬂies and mammals, is associated with simultaneous direct or
indirect Akt activation, indicating that under normal physiological
conditions, the effect of FOXO on TORC1 may occur in a temporal
manner. In ﬂies, at the organismal level, the induction of 4E-BP by
FOXO in combination with the induction of Insulin/IGF-1 receptor
transcription and mRNA translation was considered to be an adaptive
response to nutrient availability (reviewed in [47]). When nutrients
are limiting, insulin secretion is reduced and FOXO is activated. This
inhibits cell proliferation and growth by elevating 4E-BP expression as
well as Sestrin expression that inhibits TORC1. Consequently, cap-
dependent mRNA translation and the other anabolic activities of
TORC1 are repressed.
The anabolic activities of TORC1 consume nutrients and cellular
energy, and thus, reducing these activities reduces demand for
nutrients. The simultaneous induction of Insulin/IGF-1 receptor
mRNA by FOXO, in conjunction with its IRES-dependent mRNA
translation, increases the number of receptors at the cell surface,
thereby increasing sensitivity to insulin. Thus, when nutrients become
abundant, the cells are hypersensitized to the concomitant increase in
insulin levels, which inhibit FOXO and promote cell growth and
proliferation. A similar scenario could occur under other stress
conditions, such as oxidative stress when FOXO is activated by the stress
inducible kinases. If the stress conditions are prolonged, the inhibition of
TORC1 by FOXO could induce autophagy as a rescue mechanism.
Inmammalian cells, the activation of FOXO under stress conditions
promotes the inhibition of mTORC1 by inducing the expression of
Sesn3 and Rictor, which also leads to the activation of Akt. This
mechanism was shown to maintain cellular energy homeostasis
under stress conditions [28]. By shutting down the anabolic activities
of mTORC1, such as protein synthesis and lipid biosynthesis, which
consume energy, and by activating Akt, which increases energy
production, FOXO maintains cellular energy homeostasis (Fig. 4).
Through this mechanism, FOXO uncouples Akt and mTORC1 activities
and prevents energy crisis. Under normal physiological conditions,
this mechanism could constrain high mTORC1 activity. Under
conditions of reduced growth factors, FOXO is activated due to
reduced Akt activity. The regulatory circuit induced by FOXO, under
these conditions, acts in a temporal manner since it does not permit
prolonged FOXO activation and mTORC1 inhibition because of Akt
activation. However, under oxidative stress conditions, the activation
of FOXO by the stress inducible kinases is dominant to the inhibition
of FOXO activity by Akt and, thus, could induce prolonged mTORC1
Fig. 4. FOXO maintains cellular energy homeostasis by coordinating cellular supplies and demands. Under conditions of growth factor limitation or other cellular stresses, FOXO
transcription factors are activated, and inhibit the anabolic energy consuming functions of mTORC1, while activating Akt to facilitate energy producing processes. Prolonged stress
conditions and activation of mTORC1 could induce autophagy (see text for details).
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persist, the activation of mTORC1 by the FOXO-Sestrin3-AMPK axis
could induce autophagy. Notably, as was recently reported, AMPK
activation alone is sufﬁcient to induce autophagy through the direct
phosphorylation and activation of the ATG1 ortholog ULK1, which
initiates the autophagic cascade [48]. Thus, the FOXO-Sestrin3-AMPK-
mTORC1 axis could initiate autophagy both by inhibiting mTORC1,
which otherwise inhibits ULK1, and by activating AMPK, which
activates ULK1.4. Concluding remarks
The picture that has emerged from the studies described in this
review is that FOXO acts as a rheostat that, through ﬁne-tuned
mechanisms, coordinates intracellular supplies and demands. FOXO
senses extracellular environment and responds accordingly. In the
absence of extracellular stress, FOXOmaintains a cellular homeostatic
balance by preventing the hyperactivation of TORC1 relative to the
activity of Akt. However, because in absence of extracellular stress
FOXO executes this activity in a temporal manner, it would be difﬁcult
to follow this FOXO activity in a cell population, as this activity might
not be synchronized. Consequently, if FOXO activity is followed in a
population of cells in the absence of extracellular stress, it might be
concluded that FOXO is relatively dormant. Therefore, to follow and
quantify this oscillatory activity of FOXO, experiments should be
designed tomonitor the effect of FOXO on TORC1 and Akt at the single
cell level using systems biology.
In response to environmental stress, FOXO may act in a temporal
manner, but if the environmental stress is prolonged, FOXO activity
might be shifted toward the inhibitionof TORC1 to limit cellular demands
under these conditions. In this respect, FOXO acts as a “gate keeper” that
prevents cellular crisis. The activities of FOXO are consistent with its role
in cellular lifespan and aging. It remains to be determined how much of
FOXO's effect on aging is determined by its effect on TORC1. Similarly, it
should be determined how much of FOXO's role in cellular atrophy,
autophagy, and cell cycle is attributed to its effect on TORC1.
In light of the studies described in this review, the deﬁnition of
FOXO as a tumor suppressor, in that its activation has a therapeutic
advantage for cancer, becomes questionable. The suppressive effect of
FOXO activation on mTORC1 could potentially have a positive impact
on cancer therapy. However the coupling to the activation of Akt and
upstream signaling, and in particular tyrosine kinase receptorsactivation, as was shown recently [23], poses the question of whether
the inhibition of FOXO is preferredover it activation for cancer therapy.
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